uniQure N.V. (NASDAQ: QURE)’s stock price has plunge by 12.94relation to previous closing price of 5.64. Nevertheless, the company has seen a 13.54% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-15 that LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of AMT-162 in individuals with SOD1-ALS.
Is It Worth Investing in uniQure N.V. (NASDAQ: QURE) Right Now?
Additionally, the 36-month beta value for QURE is 0.93. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for QURE is 45.02M and currently, short sellers hold a 11.68% ratio of that float. The average trading volume of QURE on October 16, 2024 was 818.07K shares.
QURE’s Market Performance
QURE’s stock has seen a 13.54% increase for the week, with a 13.34% rise in the past month and a -18.34% fall in the past quarter. The volatility ratio for the week is 8.17%, and the volatility levels for the past 30 days are at 8.38% for uniQure N.V. The simple moving average for the past 20 days is 20.21% for QURE’s stock, with a 11.91% simple moving average for the past 200 days.
Analysts’ Opinion of QURE
Many brokerage firms have already submitted their reports for QURE stocks, with Raymond James repeating the rating for QURE by listing it as a “Outperform.” The predicted price for QURE in the upcoming period, according to Raymond James is $20 based on the research report published on October 10, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see QURE reach a price target of $8. The rating they have provided for QURE stocks is “Neutral” according to the report published on February 29th, 2024.
Mizuho gave a rating of “Neutral” to QURE, setting the target price at $10 in the report published on December 19th of the previous year.
QURE Trading at 9.35% from the 50-Day Moving Average
After a stumble in the market that brought QURE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.88% of loss for the given period.
Volatility was left at 8.38%, however, over the last 30 days, the volatility rate increased by 8.17%, as shares surge +6.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.05% lower at present.
During the last 5 trading sessions, QURE rose by +9.09%, which changed the moving average for the period of 200-days by -9.60% in comparison to the 20-day moving average, which settled at $5.29. In addition, uniQure N.V. saw -5.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QURE starting from Abi-Saab Walid, who sale 1,447 shares at the price of $4.36 back on Jun 26 ’24. After this action, Abi-Saab Walid now owns 115,253 shares of uniQure N.V., valued at $6,309 using the latest closing price.
CALOZ PIERRE, the Chief Operating Officer of uniQure N.V., sale 2,936 shares at $4.81 during a trade that took place back on Jun 17 ’24, which means that CALOZ PIERRE is holding 115,707 shares at $14,122 based on the most recent closing price.
Stock Fundamentals for QURE
Current profitability levels for the company are sitting at:
- -8.89 for the present operating margin
- -0.15 for the gross margin
The net margin for uniQure N.V. stands at -10.28. The total capital return value is set at -0.38. Equity return is now at value -126.41, with -34.02 for asset returns.
Based on uniQure N.V. (QURE), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2. The debt to equity ratio resting at 5.38. The interest coverage ratio of the stock is -7.58.
Currently, EBITDA for the company is -251.41 million with net debt to EBITDA at -1.07. When we switch over and look at the enterprise to sales, we see a ratio of 20.15. The receivables turnover for the company is 3.53for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.36.
Conclusion
In conclusion, uniQure N.V. (QURE) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
